| Literature DB >> 25307543 |
M J Nabais Sá1,2, H Storey3, F Flinter4, M Nagel5, S Sampaio2,6, R Castro7, J A Araújo8, M A Gaspar9, C Soares10, A Oliveira11, A C Henriques12, A G da Costa13, C P Abreu14, P Ponce15, R Alves16, L Pinho11, S E Silva17, C P de Moura18,19, L Mendonça20, F Carvalho1, M Pestana2,6, S Alves1, F Carvalho1, J P Oliveira1,2,19.
Abstract
Pathogenic mutations in genes COL4A3/COL4A4 are responsible for autosomal Alport syndrome (AS) and thin basement membrane nephropathy (TBMN). We used Sanger sequencing to analyze all exons and splice site regions of COL4A3/COL4A4, in 40 unrelated Portuguese probands with clinical suspicion of AS/TBMN. To assess genotype-phenotype correlations, we compared clinically relevant phenotypes/outcomes between homozygous/compound heterozygous and apparently heterozygous patients. Seventeen novel and four reportedly pathogenic COL4A3/COL4A4 mutations were identified in 62.5% (25/40) of the probands. Regardless of the mutated gene, all patients with ARAS manifested chronic renal failure (CRF) and hearing loss, whereas a minority of the apparently heterozygous patients had CRF or extrarenal symptoms. CRF was diagnosed at a significantly younger age in patients with ARAS. In our families, the occurrence of COL4A3/COL4A4 mutations was higher, while the prevalence of XLAS was lower than expected. Overall, a pathogenic COL4A3/COL4A4/COL4A5 mutation was identified in >50% of patients with fewer than three of the standard diagnostic criteria of AS. With such a population background, simultaneous next-generation sequencing of all three genes may be recommended as the most expedite approach to diagnose collagen IV-related glomerular basement membrane nephropathies.Entities:
Keywords: Alport syndrome; COL4A3; COL4A4; COL4A5; thin basement membrane nephropathy
Mesh:
Substances:
Year: 2014 PMID: 25307543 DOI: 10.1111/cge.12521
Source DB: PubMed Journal: Clin Genet ISSN: 0009-9163 Impact factor: 4.438